Christophe P Nicot, PhD

Professor, Pathology & Laboratory Medicine
Director, Center for Viral Pathogenesis
PhD, University of Bordeaux, France, 1995
Postdoctoral: National Cancer Institute, Uniformed Services University of the Health Sciences, Case Western Reserve University


Publications: Click here

The oncogenic human retrovirus HTLV-I is the etiological agent of an aggressive and fatal T-cell leukemia/lymphoma (ATL) disease. ATL is associated with a poor clinical prognosis and treatment of patients using conventional chemotherapy has limited benefit given that HTLV-I cells are resistant to conventional anti-cancer, apoptosis-inducing agents. In addition to ATLL, HTLV-I is also the etiological agent of an inflammatory neuro-degenerative disorder called Tropical Spastic Paraparesis/ HTLV-I-Associated Myelopathy (TSP/HAM). My laboratory studies early and late molecular events associated with cellular transformation and leukemogenesis. We are especially interested in genome instability, telomerase reactivation, RNA export and signaling pathways involved in T-cell transformation and/or virus replication. We also study new therapeutic approaches for treatment of ATL.

Nicot Lab web site.

Center for Viral Pathogenesis web site.

Selected Publications

Bellon M, Nicot C.Telomere Dynamics in Immune Senescence and Exhaustion Triggered by Chronic Viral Infection.Viruses. 2017 Oct 5;9(10).

Yeh CH, Bellon M, Pancewicz-Wojtkiewicz, Nicot C.Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients. Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):6731-6.

Bellon M, Lu L, Nicot C.Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia.Blood. 2016 May 19;127(20):2439-50.

Last modified: May 01, 2018

Contact

Christophe P Nicot, PhD
Professor, Pathology & Laboratory Medicine
Director, Center for Viral Pathogenesis

Pathology & Laboratory Medicine
3901 Rainbow Blvd
Kansas City, KS 66160

P: 913-588-6724/ Lab:913-588-7050
cnicot@kumc.edu

ID=x10503